Quarterly report pursuant to Section 13 or 15(d)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2024 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	On August 29, 2024, John Jenkins M.D., a member of the board of directors, adopted a Rule 10b5-1 plan providing for the sale of up to 5,436 shares of the Company’s common stock. Pursuant to this plan, Dr. Jenkins may sell shares of common stock beginning on November 30, 2024, subject to the terms of the agreement, and the plan terminates on November 29, 2025. The trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c). No other directors or officers adopted, modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the third quarter of 2024.
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non Rule 10b5-1 Arrangement Modified	false
John Jenkins M.D [Member]
Trading Arrangements, by Individual
Name	John Jenkins M.D
Title	board of directors
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	August 29, 2024
Rule 10b5-1 Arrangement Terminated	true
Termination Date	November 29, 2025
Arrangement Duration	457 days
Aggregate Available	5,436